Zetia Cost in Louisiana 2026: Price, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Louisiana in 2026?

Generic ezetimibe has made the medication accessible at roughly $15 per month cash price at Louisiana retail pharmacies, while brand-name Zetia carries a list price near $380 per month. The gap between those two numbers is one of the largest in any therapeutic class, and most patients in Louisiana never need to pay anywhere close to the brand price.

Ezetimibe 10 mg was first approved by the FDA in October 2002 under NDA 021445 [1]. Brand exclusivity ended, and generic versions entered the U.S. market widely after 2017. By 2026, multiple manufacturers supply generic ezetimibe tablets, which has driven the cash price down sharply. GoodRx-type coupon programs, which negotiate directly with pharmacy benefit managers, bring the retail price at chains like Walmart, Walgreens, and CVS across Louisiana to the $10, $20 per 30-tablet range for the 10 mg dose.

The manufacturer list price (wholesale acquisition cost, or WAC) for brand Zetia remains near $380 per month. That figure appears on pharmacy sticker prices before any insurance adjustment or coupon. Patients who show up at a Louisiana pharmacy with only their insurance card and a brand Zetia prescription can face out-of-pocket costs that vary widely by plan tier, but the generic path almost always costs less than $20 out of pocket.

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing dietary and biliary cholesterol absorption by approximately 54% [2]. That mechanism is distinct from statins, which inhibit hepatic cholesterol synthesis, so the two drug classes combine additively. The ACC/AHA 2019 guideline on the management of blood cholesterol specifically lists ezetimibe as the preferred non-statin add-on after maximally tolerated statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains above 70 mg/dL [3].

The IMPROVE-IT Trial: Why Ezetimibe Is Prescribed in Louisiana

IMPROVE-IT (N=18,144) established that adding ezetimibe 10 mg to simvastatin 40 mg reduced major adverse cardiovascular events by an absolute 2 percentage points (relative risk reduction 6.4%) compared with simvastatin alone over a median 6-year follow-up [4]. The trial was published in the New England Journal of Medicine in 2015 and remains the foundational outcomes evidence for ezetimibe use. LDL-C in the combination arm fell to a median of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only group [4].

The trial enrolled patients who had experienced an acute coronary syndrome within 10 days of randomization. A prespecified diabetic subgroup (n=4,933) showed a larger absolute cardiovascular benefit, with a 5.5 percentage point reduction in the primary endpoint [5]. That subgroup finding is directly relevant in Louisiana, which has one of the highest prevalence rates of type 2 diabetes in the United States, approximately 14.8% of adults, compared with a national average near 11.6% [6].

A 2022 Cochrane review of ezetimibe trials (27 RCTs, N=78,945) confirmed that ezetimibe reduces LDL-C by 18 to 25% as monotherapy and by an additional 21 to 27% when added to a statin baseline, without a clinically significant increase in adverse events compared with placebo [7]. The safety profile matters for tolerability in statin-intolerant patients, a population that represents a meaningful fraction of Louisiana cardiology referrals.

Louisiana Medicaid Coverage for Ezetimibe: What the PDL Actually Says

Louisiana Medicaid does not cover ezetimibe (Zetia or generic) as a standard preferred drug list (PDL) benefit in 2026. Ezetimibe is not listed as a preferred agent on the Louisiana Medicaid Pharmacy PDL published by the Louisiana Department of Health [8]. Patients enrolled in Louisiana Medicaid, including both fee-for-service and Medicaid managed care plans, who need ezetimibe must pursue a prior authorization exception or pay cash.

Prior authorization for a non-PDL drug under Louisiana Medicaid typically requires documentation of an ASCVD diagnosis, LDL-C above guideline thresholds despite maximally tolerated statin therapy, and a note from the prescribing physician. Approval is not guaranteed. Prescribers who submit PA requests for ezetimibe should cite the ACC/AHA 2019 guideline Class IIa recommendation (LOE A) directly [3].

Louisiana Medicaid covers approximately 1.9 million residents, or about 41% of the state's population, through the expanded Medicaid program [9]. Given the state's elevated rates of cardiovascular disease and diabetes, the coverage gap for ezetimibe creates a real access barrier. At $15 per month cash price for the generic, however, many Medicaid patients can afford the medication out of pocket if their prescriber explains the generic pricing.

The HealthRX Cardiovascular Access Framework for Louisiana patients on Medicaid:

1. Confirm generic ezetimibe 10 mg availability at the patient's nearest pharmacy (Walmart $4 generic lists sometimes include it; verify locally).
2. Apply a GoodRx or similar discount coupon to bring the price to $10, $20 per month before attempting a PA.
3. Submit PA only if the patient cannot afford the cash price or if specialty formulary coverage is available through a managed care plan.
4. Document LDL-C lab values, ASCVD diagnosis code (ICD-10 I25.10 or similar), and the specific ACC/AHA guideline text in the PA letter.

Which Commercial Insurance Plans Cover Ezetimibe in Louisiana?

Most commercial insurers operating in Louisiana cover generic ezetimibe, typically on Tier 1 or Tier 2 of the formulary, which means a $5, $30 copay per 30-day supply. Brand Zetia, by contrast, lands on Tier 3 or Tier 4 at most plans, producing copays of $60, $150 or more per month before deductibles.

The major insurance carriers with significant Louisiana enrollment, Blue Cross Blue Shield of Louisiana, Humana, Aetna, and UnitedHealthcare, all list generic ezetimibe as a covered preferred generic on their 2026 individual and group market formularies [10]. Patients should specifically request generic ezetimibe rather than brand Zetia at the pharmacy counter, because automatic generic substitution is not always triggered for oral tablets in Louisiana if the prescriber writes "Zetia" on the script.

Medicare Part D plans in Louisiana follow CMS formulary guidelines. Ezetimibe appears on most Part D formularies; however, tier placement and cost-sharing vary by plan. The Medicare Extra Help (Low Income Subsidy) program caps copays at $4.50 for generics in 2026 for qualifying beneficiaries [11]. Patients whose annual income is at or below 150% of the federal poverty level should apply through the Social Security Administration.

Employer-sponsored plans in Louisiana generally follow the same pattern: generic ezetimibe is covered, brand Zetia requires step therapy or PA. The Louisiana Department of Insurance does not mandate cardiovascular drug coverage beyond minimum ACA essential health benefits, so plan-specific formulary checks are necessary before prescribing [12].

Compounded Ezetimibe in Louisiana: 503A Rules and Legality

Compounded ezetimibe is legal in Louisiana when prepared by a 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Louisiana's pharmacy compounding rules align with federal DQSA (Drug Quality and Security Act) requirements, and the Louisiana Board of Pharmacy enforces 503A standards [13].

A 503A pharmacy compounds for individual patients based on a specific prescription. The pharmacist may combine ezetimibe with other active pharmaceutical ingredients (for example, a statin or plant sterol), adjust the dose form, or prepare the drug without certain excipients for patients with documented allergies or intolerances. Compounded ezetimibe is not FDA-approved, meaning the specific formulation has not undergone the same stability and bioequivalence testing as the commercial tablet. Prescribers and patients should understand that distinction.

Cost is the main driver of interest in compounded ezetimibe in Louisiana. Some 503A compounding pharmacies offer compounded ezetimibe as part of a cardiovascular lipid-management protocol at low or no out-of-pocket cost when paired with a telehealth membership or cash-pay clinical program. With commercial generic ezetimibe already available for $15 per month, the cost advantage of compounding is narrower than in drug classes where no cheap generic exists. The clinical rationale for compounding ezetimibe is strongest when a patient needs a custom dose, a specific excipient-free formulation, or a combination product not commercially available.

The FDA does not permit compounding of drugs that are commercially available in exactly the same strength and dose form without a specific medical need documented on the prescription [14]. Prescribers in Louisiana who write for compounded ezetimibe 10 mg plain oral tablets, identical to the commercial generic, should document the clinical rationale clearly to stay compliant with both FDA guidance and Louisiana Board of Pharmacy requirements.

Telehealth Prescribing of Ezetimibe in Louisiana: Legal Pathway

Telehealth prescribing of ezetimibe is fully legal in Louisiana as of 2026. Ezetimibe is not a controlled substance, so it does not trigger DEA special telemedicine prescribing rules. A Louisiana-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via synchronous audio-video telehealth, review a lipid panel, assess cardiovascular risk using the ACC/AHA Pooled Cohort Equations [3], and send an electronic prescription for ezetimibe to any Louisiana pharmacy, all in a single visit.

Louisiana Act 225 (2020) and subsequent amendments expanded telehealth parity, requiring that commercial insurers reimburse telehealth evaluation and management visits at the same rate as in-person visits for the same service [15]. That parity provision means a telehealth prescribing visit for ezetimibe through a service like HealthRX should be covered by most Louisiana commercial plans at the same cost-sharing as an office visit.

Patients should have a recent lipid panel (within the past 12 months at minimum, ideally within 3 months) before a telehealth ezetimibe consultation. The ACC/AHA guideline requires baseline LDL-C documentation to justify add-on therapy, and the prescribing clinician must assess fasting lipid values, hepatic function, and ASCVD risk category before initiating therapy [3]. A telehealth visit without labs is incomplete for new ezetimibe initiation.

Follow-up labs 4 to 12 weeks after starting ezetimibe should confirm the expected 18 to 25% LDL-C reduction [7]. If LDL-C does not fall by at least 15%, the prescriber should verify adherence, check whether the patient is taking the tablet daily (ideally at the same time), and consider whether an alternative lipid-lowering agent is needed.

Cheapest Ways to Get Ezetimibe in Louisiana: A Direct Comparison

The cash price for generic ezetimibe in Louisiana in 2026 is approximately $15 per month at retail. Prices at specific chains vary:

Walmart and Sam's Club pharmacies list ezetimibe 10 mg on their $4/$10 generic program in some states; Louisiana availability on that specific list should be verified at the pharmacy counter, as the program varies by location. Even outside that program, GoodRx coupons consistently bring the price below $15 at Walmart, Walgreens, and CVS locations across Baton Rouge, New Orleans, Shreveport, and Lafayette.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic ezetimibe at approximately $6 for 30 tablets plus a dispensing fee, shipping to Louisiana [16]. That is currently one of the lowest available prices for any Louisiana patient with a valid prescription and reliable mail delivery.

The Merck Zetia Savings Card applies only to brand Zetia and is not valid for Medicaid or Medicare beneficiaries. For commercially insured patients on brand Zetia whose plan places the drug on Tier 3 or 4, the savings card can reduce copays, but switching to generic ezetimibe 10 mg eliminates the need for a brand savings card entirely. Generic ezetimibe is therapeutically equivalent to brand Zetia per FDA bioequivalence standards [1].

Patient assistance programs from Merck (Merck Helps) provide free brand Zetia to uninsured or underinsured patients who meet income criteria, generally at or below 200% of the federal poverty level [17]. The application process takes 2 to 4 weeks and requires a prescriber signature, proof of income, and proof of insurance (or lack thereof).

Ezetimibe Safety, Monitoring, and Drug Interactions in Louisiana Clinical Practice

Ezetimibe has a favorable adverse event profile. In IMPROVE-IT (N=18,144), rates of muscle-related adverse events, liver enzyme elevations, and cancer were not statistically different between the ezetimibe-statin group and the statin-only group (P<0.05 threshold not reached for any safety endpoint) [4]. That data addresses the concern, sometimes raised by patients, that ezetimibe causes the same myopathy risk as statins. The intestinal mechanism of ezetimibe does not involve skeletal muscle.

Clinically relevant drug interactions are limited. Cyclosporine increases ezetimibe plasma concentrations by approximately 3.4-fold; dosing requires adjustment in transplant patients [18]. Fibrates (fenofibrate, gemfibrozil) can increase ezetimibe glucuronide levels, and the combination requires monitoring for cholelithiasis. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by approximately 55% if taken simultaneously; they should be administered at least 2 hours before or 4 hours after ezetimibe [1].

Baseline hepatic function testing before initiating ezetimibe is not required by the FDA label, in contrast to statin monitoring requirements. However, patients with moderate or severe hepatic impairment (Child-Pugh B or C) should not receive ezetimibe, as glucuronidation is impaired and drug exposure increases significantly [1]. Louisiana clinicians prescribing via telehealth should screen for hepatic disease history during the intake assessment.

Pregnancy category: ezetimibe is contraindicated in pregnancy (FDA pregnancy category X when combined with a statin) [1]. Women of childbearing age in Louisiana should receive clear counseling about contraception before initiating any statin-ezetimibe regimen. Ezetimibe alone has less established teratogenic data but is generally avoided during pregnancy due to the importance of cholesterol in fetal development [19].

Ezetimibe vs. PCSK9 Inhibitors in Louisiana: Sequencing Decisions

The ACC/AHA 2019 guideline recommends ezetimibe before PCSK9 inhibitors (evolocumab, alirocumab) in the add-on therapy sequence for very-high-risk ASCVD patients [3]. The cost difference is stark: ezetimibe at $15 per month versus PCSK9 inhibitors at $500, $700 per month list price, though patient assistance and manufacturer programs reduce the PCSK9 out-of-pocket cost substantially for some patients.

In the FOURIER trial (N=27,564), evolocumab added to statin therapy reduced major cardiovascular events by 15% relative risk reduction over a median 2.2 years, with LDL-C falling to a median of 30 mg/dL [20]. In ODYSSEY OUTCOMES (N=18,924), alirocumab reduced major cardiovascular events by 15% relative risk reduction over a median 2.8 years [21]. Both PCSK9 trials enrolled patients already on maximally tolerated statin therapy without ezetimibe, so the incremental benefit of sequencing ezetimibe first, then PCSK9 if LDL-C remains above 70 mg/dL, reflects the guideline logic rather than head-to-head data.

For Louisiana prescribers evaluating a patient on atorvastatin 40 mg with LDL-C of 85 mg/dL and established ASCVD: adding ezetimibe 10 mg would be expected to lower LDL-C by approximately 21 mg/dL (25% of 85 mg/dL), bringing the patient to approximately 64 mg/dL, below the 70 mg/dL guideline threshold. That response avoids PCSK9 costs entirely for a meaningful proportion of patients [3].